Labiotech.eu

More News! 8 Dec 2022

Enhertu’s positive results demonstrate improvement in overall survival

Enhertu, an antibody drug conjugate, being jointly developed by Daiichi Sankyo and AstraZeneca, has demonstrated a statistically significant and clinically meaningful improvement in overall survival. Updated results from DESTINY-Breast03 phase 3 trial showed Enhertu (trastuzumab deruxtecan) was performing better than trastuzumab emtansine (T-DM1) in patients with HER2 positive unresectable and/or metastatic breast cancer previously treated […]

December 8, 2022 - 4 minutesmins - By Liza Laws

News and Trends 8 Dec 2022

MicrofluidX raises £3.3M to develop advanced therapy manufacturing platform

MicrofluidX (MFX), a U.K. based provider of next-generation bioreactors for cell research and manufacturing, has announced £3.3 million ($4 million) of secured investments. This brings the company’s total funding to date to £7 million ($8.5 million). MicrofluidX’s next generation platform, the Cyto Engine, addresses the need for an affordable, scalable cell culture platform to revolutionize […]

December 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

MetrioPharm reveals COVID-19 study data

MetrioPharm AG, a Swiss pharmaceutical company developing drugs for inflammatory diseases, has announced topline data from its CT05 phase IIa study of small molecule macrophage metabolic modulator MP1032 in COVID-19 patients. In the trial, patients received either MP1032 plus standard of care (SoC), or placebo plus SoC. SoC partially included other antivirals (Remdesivir or Nirmatrelvir/Ritonavir), […]

December 8, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

New method uses metabolism to detect cancers

When cancer is detected at an early stage, the rates of survival increase drastically, but today only a few cancer types are screened for. An international study led by researchers from Chalmers University of Technology, Sweden, shows that a new, previously untested method can easily find multiple types of newly formed cancers at the same […]

December 8, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Novadip bone healing trial yields positive results

Novadip Biosciences SA has announced positive data from its phase 1/2 clinical trial evaluating the safety and clinical activity of its investigational product, NVD-003. The study was on patients with severe bone non-union (BNU) of the lower limb following trauma. Novadip is a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to […]

December 8, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Laevoroc Oncology pushes for relapsed leukemia cure

Laevoroc Oncology, a privately-owned, Swiss oncology development company, has announced the publication of key preclinical data carried out at the University of California, Los Angeles (UCLA), which provides mechanistic insights into the immunoregulatory functions of purine nucleoside phosphorylase (PNP) with Laevoroc’s PNP inhibitor, LR 09. The research shows that PNP is a novel metabolic immune […]

December 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders

Sosei Heptares has entered translational medicine and R&D agreements with the MRC Weatherall Institute of Molecular Medicine at the University of Oxford, U.K., and KU Leuven, Belgium. Sosei Heptares focuses on G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development. The focus of the agreements is to apply the innovative technologies and research […]

December 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Allergy Therapeutics moves ahead with peanut and grass pollen allergy trials

Allergy Therapeutics has announced the first subject has been dosed in the pivotal phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL. Grass MATA MPL is Allergy Therapeutics’ short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate, which aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen. Grass […]

December 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

DNA repair mechanism study could boost cancer treatment

A better understanding of the mechanisms involved in DNA repair may pave the way for developing inhibitors to improve the effectiveness of radiation therapy. Nucleotide excision repair (NER) is a critical DNA repair pathway that plays a key role in maintaining transcription and genome integrity by removing bulky DNA lesions. The key steps in the […]

December 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 8 Dec 2022

Metrion and KCNC1 Foundation announce collaboration to identify therapeutic

Metrion Biosciences Limited, and The KCNC1 Foundation are to collaborate to try and find a therapeutic for children. The KCNC1 Foundation is a not-for-profit organization focused on the development of a treatment for an ultra-rare genetic disorder. Variants of the KCNC1 gene impact Kv3.1 potassium channel function, resulting in neurodevelopmental disorders, which can include progressive […]

December 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Dec 2022

Polyplus announces completion of acquisition of Xpress Biologics to expand plasmid DNA

Polyplus has announced the completion of an acquisition of Belgian Xpress Biologics to expand plasmid DNA technology. Xpress Biologics specializes in the production of plasmid DNA and protein using microbial expression systems. Polypus concentrates on the manufacturing of advanced therapeutic medicinal products from research to commercial grade. The acquisition will strategically expand the Polyplus plasmid […]

December 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 7 Dec 2022

Ibex and Source announce agreement to aid pathologists with diagnostic accuracy

An agreement has been announced between Ibex Medical Analytics and Source LDPath, part of Source BioScience. It will expand the deployment of artificial intelligence (AI) to Source’s entire pathology network. Ibex works with AI-powered cancer diagnostics and the expansion builds on its previous work with LDPath. Source, which provides integrated laboratory services and products, acquired […]

December 7, 2022 - 3 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Enhertu’s positive results demonstrate improvement in overall survival

MicrofluidX raises £3.3M to develop advanced therapy manufacturing platform

MetrioPharm reveals COVID-19 study data

New method uses metabolism to detect cancers

Novadip bone healing trial yields positive results

Laevoroc Oncology pushes for relapsed leukemia cure

Sosei Heptares signs R&D agreements on gastrointestinal and immune disorders

Allergy Therapeutics moves ahead with peanut and grass pollen allergy trials

DNA repair mechanism study could boost cancer treatment

Metrion and KCNC1 Foundation announce collaboration to identify therapeutic

Polyplus announces completion of acquisition of Xpress Biologics to expand plasmid DNA

Ibex and Source announce agreement to aid pathologists with diagnostic accuracy

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!